Lumida
/AVAH
⌘K
Aveanna Healthcare Holdings Inc

Aveanna Healthcare Holdings Inc

AVAH
$14.08USD↑+1.59%+0.22 today

MARKET CAP

3.1B

P/E (TTM)

11.6x

FWD P/E

—

DAY RANGE

$14 – $15

52W RANGE

$6
$15

AI Summary

Stalk
StalkMedium

AVAH exhibits a strong parabolic up-move from its base breakout, supported by robust volume and relative strength. While the medium-term structure remains bullish within a Stage 2 advancing regime, price is extended and overbought in the short term. Execution is best deferred, stalking for a shallow pullback into the rising 9–20 EMA zone. A failure to hold this area would signal a loss of trend integrity.

  • ↑Q2 revenue of $670M (+13.7% YoY) and adjusted EBITDA of $95.4M (+8%).
  • ↑Preferred payer network at 37 agreements (64% of MCO volume), targeting 38 by 2026-end.
  • ↓Persistent labor market pressure may constrain staffing and growth.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Aveanna Healthcare Holdings, Inc. (NASDAQ: AVAH) is a leader in the home and community-based care sector, focusing on providing essential services such as private duty nursing, home health, hospice, and medical solutions. The company is strategically positioned to capitalize on the increasing demand for high-quality, cost-effective healthcare solutions, particularly amidst ongoing shifts in government policies that favor home care options over institutionalized care settings.

Bull says

  • ↑Q2 revenue of $670M (+13.7% YoY) and adjusted EBITDA of $95.4M (+8%).
  • ↑Preferred payer network at 37 agreements (64% of MCO volume), targeting 38 by 2026-end.
  • ↑Liquidity of ~$433M and YTD free cash flow of $131M support growth funding.
  • ↑2026 guidance: revenue >$2.68B and adjusted EBITDA >$365M under current trends.
  • ↑Government and value-based care shifts favor home-based services demand.
  • ↑Strong profitability factors and healthy earnings yield underscore solid fundamentals.

Bear says

  • ↓Persistent labor market pressure may constrain staffing and growth.
  • ↓High dependence on Medicaid/Medicare reimbursement poses funding risk.
  • ↓Stock exhibits elevated volatility and weak quality metrics, deterring some investors.
  • ↓Concentration in key payer agreements (64% of volume) raises partner risk.
  • ↓Family First integration still early, with potential execution and cost drag.
  • ↓Negative book-to-price and lack of dividend yield signal valuation concerns.

Investment themes with AVAH

Health Care Providers↓ -0.37%

UNH · CVS · HCA

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-14-2026neutral

Transcript signals

Bull points

  • And I think, to your point, stronger than where we thought we would be this time of year, but also a nice horizon for the rest of the year. And I think on all fronts, cash flow is going to be a really good story for Aviana this year and certainly much stronger than we had expected coming into this year.
  • Revenue for the second quarter was approximately $590 million, representing a 16.8% increase over the prior year period.
  • Second quarter adjusted EBITDA was $88.3 million, representing a 93.6% increase over the prior year period primarily due to the improved rate environment and continued cost savings initiatives.

Bear points

  • While we continue to operate in a challenging environment, our preferred payer strategy supports our ability to achieve normalized growth rates in all three of our business segments.
  • we are experiencing general headwinds with state Medicaid directors and governors as they plan for less overall Medicaid funding and the possibility of shouldering more of their Medicaid costs in the future.
  • we were disappointed by the significance of the proposed cuts, totaling 6.4%. This proposed rule would be a direct cut to Medicare and seniors receiving and expecting to receive health care at home.
Read full transcript analysis ›